Former Walgreens executive joins board of directors at rapidly growing leader in medication adherence solutions
BRENTWOOD, Tenn., April 4, 2019 – AdhereHealth™, a leading healthcare technology company focused on medication adherence, has added healthcare veteran Brad Fluegel to its board of directors. Fluegel, formerly chief healthcare commercial market development officer for Walgreens, joins AdhereHealth’s board during a period of expansive growth for the company.
AdhereHealth’s proprietary technology, the Adhere Platform™, targets an estimated $300 billion in annual unnecessary medical costs caused by gaps in medication adherence. The Adhere platform uses advanced analytics, home-delivered pharmacy and AdhereHealth’s national footprint of licensed clinicians to navigate social determinants. This unprecedented combination enables AdhereHealth to partner with clients by offering a unique guaranteed fee structure for each consumer’s quality measure conversion.
“AdhereHealth’s approach to improve healthcare outcomes through medication adherence is showing unprecedented impact on quality and reduced healthcare costs,” said Fluegel. “I’m thrilled to join the company’s board and support the company’s mission to improve health through AdhereHealth’s advanced technologies and adherence solutions.”
Prior to Fluegel’s most recent senior leadership position at Walgreens, Fluegel was chief strategy and external affairs officer at WellPoint (now Anthem) and head of national accounts at Aetna. He currently serves on the boards of Fitbit, Premera Blue Cross and Metropolitan Jewish Health System.
About AdhereHealth™
AdhereHealth™ is a healthcare technology solutions leader supporting health plans, self-insured employers and other risk-bearing entities for medication adherence insights and improved healthcare outcomes. The company’s Adhere Platform™ touches nearly 10 million consumers through advanced technologies, at-risk engagement services and home-delivered pharmacy. The integrated set of solutions address an estimated $300 billion of unnecessary annual medical costs attributed to medication
